Niloy J Samadder
University of Wisconsin Carbone Cancer Center - University Hospital · Mayo Clinic in Rochester · Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Niloy J Samadder as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:12 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06557733 · An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous PolyposisNational Cancer Institute (NCI) · recruiting · Colorectal Carcinoma, Familial Adenomatous Polyposis · principal investigator
- N/ANCT04674228 · Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01National Cancer Institute (NCI) · terminated · Familial Adenomatous Polyposis · principal investigator
- Ph1NCT04456140 · Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit StudyMayo Clinic · completed · Breast Carcinoma, Digestive System Neoplasm, Malignant Brain Neoplasm · principal investigator
- Ph2NCT02961374 · Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon CancerNational Cancer Institute (NCI) · completed · Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis · principal investigator
- Ph2NCT01187901 · A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis PatientsUniversity of Utah · completed · Adenomatous Polyposis Coli · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Multi-cancer Early DetectionR01CA214679 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2025 to 2026 · $445,446 awarded in 2026Same name and institution; not confirmed by an ID
- Metabolomic Strategies to Identify Biomarkers of Chemoprevention in FAP PatientsR21CA217130 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · fiscal years 2017 to 2018 · $170,447 awarded in 2018Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- UW Comprehensive Cancer Center SupportP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · fiscal years 2018 to 2026Named on NCT06557733
- University of Arizona Cancer Prevention Clinical Trials NetworkUG1CA242596 · NCI · UNIVERSITY OF ARIZONA · PI Julie E Bauman, Patricia Ann Thompson · fiscal years 2019 to 2026Named on NCT06557733
- The MW Cancer Prevention Clinical Trials NetworkUG1CA242635 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Lisa M Barroilhet · fiscal years 2020 to 2024Named on NCT06557733
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2018 to 2026Named on NCT04674228, NCT02961374
- P01CA073992RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01187901
Most cited trial papers
Clinical-trial papers with this author name in colorectal cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:12 UTC. The ranking covers the 200 most relevant of 11 PubMed records, and a shared surname and initials can bring in a namesake. All 11 on PubMed
- 118 citationsRCR 3.7
- 69 citationsRCR 2.6
- Comparing tailored and narrative worksite interventions at increasing colonoscopy adherence in adults 50-75: a randomized controlled trial.Soc Sci Med · 201463 citationsRCR 2.7
- Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis.N Engl J Med · 202063 citationsRCR 2.8
- 58 citationsRCR 2.7
- 33 citationsRCR 1.1
- 22 citationsRCR 2.6
- Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.Cancer Prev Res (Phila) · 201820 citationsRCR 0.7
- Combination of Sulindac and Eflornithine Delays the Need for Lower Gastrointestinal Surgery in Patients With Familial Adenomatous Polyposis: Post Hoc Analysis of a Randomized Clinical Trial.Dis Colon Rectum · 202220 citationsRCR 1.5